Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Neoplasms 2Hematologic Diseases 2Thrombocytosis 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Polycythemia 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hemorrhagic Disorders 1EGFR Mutated EGFR TKI Naive Metastatic NSCLC 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1

Interventions

Imatinib Mesylate 5ruxolitinib 4ponatinib 4nilotinib 411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 4Azacitidine 3fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1pembrolizumab 1ibrutinib 1bosutinib 1Zoledronic Acid 1Watchful Waiting 1Sertraline 1SCIO-469 1Quality of Life 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Marrow Diseases × N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide × Clear all
NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sierra Oncology LLC - a GSK company

Phase 2 Terminated
39 enrolled
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡